Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Multi-center, Prospective, Randomized, Double-blind, Placebo- Controlled Study to Evaluate the Effectiveness and Safety of ZP5-9676 for the Treatment of Hookworm (Ancylostoma Duodenale and Necator Americanus), Ascaris Lumbricoides, and Trichuris Trichiura in Pediatric and Adult Participants

NCT06128447 is registered in ClinicalTrials.gov with Zero Point Five Therapeutics as lead sponsor.

NCT NCT06128447
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06128447 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Multi-center, Prospective, Randomized, Double-blind, Placebo- Controlled Study to Evaluate the Effectiveness and Safety of ZP5-9676 for the Treatment of Hookworm (Ancylostoma Duodenale and Necator Americanus), Ascaris Lumbricoides, and Trichuris Trichiura in Pediatric and Adult Participants
Lead sponsor
Zero Point Five Therapeutics
Phase
Phase 3
Overall status
Recruiting
Start date
February 14, 2025
Completion date
March 31, 2027
Enrollment
300 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

soil-transmitted helminthiasis (sth)